Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex.
Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex.
复制标题
艾滋病和艾滋病相关综合症患者齐多夫定的安慰剂对照试验的生活质量。
DOI：
--
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
D. D. Richman
中科院分区：
文献类型：
--
作者：
Wu Aw;William C. Mathews;Lucy T. Brysk;J. H. Atkinson;Igor Grant;I. Abramson;C. Kennedy;McCutchan Ja;Stephen A. Spector;D. D. Richman
在齐多夫定安慰剂对照试验中，我们使用Karnofsky体能状态和幸福感质量量表（QWB）测量了31例艾滋病和艾滋病相关综合征患者的生活质量。16名患者随机接受齐多夫定治疗，15名患者随机接受安慰剂治疗。我们在1年内记录了每位患者的9个评分。在盲法试验期间，3名接受安慰剂的患者死亡;在1年时，齐多夫定组有1人死亡，安慰剂组有10人死亡。重复测量方差分析表明，齐多夫定组的平均得分下降小于安慰剂组在盲法试验（p <0.03）和1年（p <0.002）。然而，由于QWB将死亡纳入其评分，这些结果在很大程度上反映了死亡率的差异。当排除死亡者的数据时，齐多夫定组在盲法试验结束时的Karnofsky评分较高（p <0.02），但在1年时，两组之间没有观察到显著差异。QWB和其他生活质量指标可能有助于更全面地评估艾滋病治疗，并可能更早地发现治疗效果。现有的措施是否能检测出幸存者之间的真实的差异，将需要在病情较轻的患者中进行测试。
We measured quality of life using the Karnofsky Performance Status and Quality of Well-Being scale (QWB) for 31 patients with AIDS and AIDS-related complex in a placebo-controlled trial of zidovudine. Sixteen patients were randomized to zidovudine and 15 to placebo. We recorded nine scores for each patient during 1 year. During the blinded trial, 3 patients receiving placebo died; at 1 year, one had died in the zidovudine group and 10 in the placebo group. Repeated-measures analysis of variance demonstrated that mean scores declined less for the zidovudine group than for the placebo group during the blinded trial (p less than 0.03) and during 1 year (p less than 0.002). However, because the QWB incorporates death into its score, these results largely reflected differences in mortality. When data from those who died were excluded, Karnofsky scores were higher for the zidovudine group at the end of the blinded trial (p less than 0.02), but at 1 year no significant differences were observed between groups. The QWB and other quality-of-life measures may contribute to more comprehensive evaluation of AIDS treatments, and may detect treatment effects earlier. Whether existing measures can detect real differences among survivors will require testing in patients with less advanced disease.